NMRA Stock News & Catalysts

FEATURED

Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in

Summary

Aug 14, 2026, 7:00 AM ·Globe Newswire

RECENT

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms

Jul 27, 2026, 7:00 AM ·Globe Newswire

NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud

Neumora Therapeutics projected cash runway "into 2027" tied to clinical milestones that never materialized -- then cut 35% of its workforce the same day both pivotal trials failed. Neumora Therapeutics

Jun 18, 2026, 10:05 AM ·Business Wire

NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations

Neumora Therapeutics characterized its first failed Phase 3 trial as an "anomaly" and projected 90% statistical power across its navacaprant program -- then both remaining pivotal trials failed, triggering

Jun 17, 2026, 9:07 AM ·PRNewswire

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%.NEW YORK, June 16, 2026 /PRNewswire/ -- Neumora Therapeutics (NASDAQ:NMRA) shareholders lost significant value today after

Jun 16, 2026, 4:44 PM ·PRNewswire

NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.

ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ:NMRA) complied with federal securities laws. On June 15,

Jun 15, 2026, 12:46 PM ·Globe Newswire

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer's disease agitation, NMRA-898

Jun 15, 2026, 8:00 AM ·Globe Newswire

Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms

May 12, 2026, 4:05 PM ·Globe Newswire

Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer's disease agitation and NMRA-898 in

May 7, 2026, 7:00 AM ·Globe Newswire

Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference

WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms

Apr 6, 2026, 7:00 AM ·Globe Newswire

Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for

Mar 30, 2026, 6:53 AM ·Globe Newswire

NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, March 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc.

Mar 25, 2026, 4:32 PM ·Globe Newswire

NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder

Mar 19, 2026, 7:27 PM ·Business Wire

Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026

WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms

Mar 16, 2026, 7:00 AM ·Globe Newswire

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms

Feb 4, 2026, 7:00 AM ·Globe Newswire

Neumora Therapeutics, Inc. Common Stock NMRA · News